Dermata Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
DRMA Nasdaq 2830 www.dermatarx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dermata Therapeutics, Inc.

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - May 14th, 2025 7:00 am
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - Apr 15th, 2025 6:30 am
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Mar 27th, 2025 6:15 pm
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints - Mar 27th, 2025 6:00 am
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results - Mar 17th, 2025 2:16 pm
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - Mar 4th, 2025 6:03 am
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - Feb 25th, 2025 5:58 am
Dermata to Present on BioPub on January 31, 2025 - Jan 29th, 2025 2:05 pm
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Jan 23rd, 2025 2:15 pm
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Jan 22nd, 2025 6:00 am
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) - Jan 21st, 2025 6:00 am
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - Dec 16th, 2024 7:00 am
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - Dec 10th, 2024 7:00 am
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - Dec 3rd, 2024 7:00 am
Life Sciences Investor Forum: Presentations Now Available for Online Viewing - Nov 15th, 2024 6:35 am
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Nov 13th, 2024 2:15 pm
Life Sciences Investor Forum Agenda Announced for November 14th - Nov 12th, 2024 6:35 am
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 - Nov 11th, 2024 6:35 am
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 - Oct 8th, 2024 2:15 pm
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Sep 17th, 2024 3:15 pm